Forsta AP Fonden Increases Stock Position in Centene Co. (NYSE:CNC)

Forsta AP Fonden raised its position in Centene Co. (NYSE:CNC - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 206,800 shares of the company's stock after buying an additional 8,000 shares during the period. Forsta AP Fonden's holdings in Centene were worth $12,528,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in CNC. Mount Yale Investment Advisors LLC boosted its holdings in shares of Centene by 2.1% during the 3rd quarter. Mount Yale Investment Advisors LLC now owns 8,082 shares of the company's stock worth $608,000 after purchasing an additional 167 shares during the last quarter. Aptus Capital Advisors LLC grew its holdings in Centene by 6.2% in the 3rd quarter. Aptus Capital Advisors LLC now owns 3,722 shares of the company's stock valued at $280,000 after buying an additional 217 shares in the last quarter. CX Institutional increased its stake in shares of Centene by 7.3% in the 3rd quarter. CX Institutional now owns 3,919 shares of the company's stock worth $295,000 after acquiring an additional 266 shares during the last quarter. Forte Capital LLC ADV boosted its position in shares of Centene by 5.5% during the 3rd quarter. Forte Capital LLC ADV now owns 5,320 shares of the company's stock valued at $400,000 after acquiring an additional 275 shares during the last quarter. Finally, GAM Holding AG increased its position in Centene by 0.3% during the third quarter. GAM Holding AG now owns 88,973 shares of the company's stock worth $6,698,000 after purchasing an additional 288 shares during the last quarter. 93.63% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CNC has been the topic of several analyst reports. Truist Financial reduced their price target on shares of Centene from $89.00 to $84.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. Sanford C. Bernstein lowered their target price on shares of Centene from $96.00 to $88.00 and set an "outperform" rating for the company in a research note on Wednesday, October 30th. Wells Fargo & Company lowered their price objective on shares of Centene from $91.00 to $90.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. StockNews.com upgraded Centene from a "buy" rating to a "strong-buy" rating in a research note on Monday. Finally, Barclays increased their target price on Centene from $91.00 to $93.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Centene presently has a consensus rating of "Moderate Buy" and an average target price of $80.92.

Centene Stock Up 0.4 %

NYSE:CNC traded up $0.24 during trading hours on Thursday, hitting $64.15. The company's stock had a trading volume of 731,755 shares, compared to its average volume of 4,001,258. The stock has a market capitalization of $32.38 billion, a P/E ratio of 11.13, a price-to-earnings-growth ratio of 0.85 and a beta of 0.45. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. The stock has a fifty day moving average of $61.01 and a 200-day moving average of $67.19. Centene Co. has a 52-week low of $55.03 and a 52-week high of $81.42.

Insider Activity

In related news, Director H James Dallas acquired 1,693 shares of the firm's stock in a transaction on Monday, December 16th. The stock was bought at an average price of $59.01 per share, for a total transaction of $99,903.93. Following the completion of the purchase, the director now directly owns 1,693 shares of the company's stock, valued at approximately $99,903.93. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Thomas Greco bought 17,000 shares of Centene stock in a transaction dated Wednesday, December 18th. The stock was purchased at an average cost of $59.75 per share, with a total value of $1,015,750.00. Following the completion of the acquisition, the director now directly owns 19,309 shares in the company, valued at approximately $1,153,712.75. The trade was a 736.25 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 45,010 shares of company stock worth $2,660,276. 0.33% of the stock is currently owned by insiders.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support.